North East and North Cumbria
ICS Formulary
ICS Formulary
2 Cardiovascular system
02-15 SGLT-2 inhibitor
| Dapagliflozin |
|
First Choice
|
5mg and 10mg tablets Approved in line with NICE for treatment of:
For details on use in diabetes and chronic kidney disease please see entry in 06.01.02.03 |
 NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction NICE TA902: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction |
|
| Empagliflozin Jardiance® |
|
Formulary
|
10mg and 25mg tablets Approved in line with NICE for the treatment of:
For details on use in diabetes and chronic kidney disease please see entry in 06.01.02.03 |
|
NICE TA773: Empagliflozin for treating chronic heart failure with reduced ejection fraction NICE TA929: Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction |
|
|
Links
- Academic Health Science Network (North East and North Cumbria) - Atrial Fibrilation
- NICE NG148: Acute kidney injury: prevention, detection and management
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction
- NICE TA773: Empagliflozin for treating chronic heart failure with reduced ejection fraction
- NICE TA902: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
- NICE TA929: Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
- North East Guideline For Use Of Sodium Glucose Co transporter 2 Inhibitors (SGLT2i)